Retraction notice to “Effects of aged garlic extract on blood pressure in hypertensive patients: A systematic review and meta-analysis of randomized controlled trials” [PRO 175 (2024) 106914]
Retraction notice to “Effects of aged garlic extract on blood pressure in hypertensive patients: A systematic review and meta-analysis of randomized controlled trials” [PRO 175 (2024) 106914]. // Prostaglandins & Other Lipid Mediators. – URL: https://www.sciencedirect.com/science/article/pii/S1098882326000456?dgcid=rss_sd_all
Retraction notice to “Effects of aged garlic extract on blood pressure in hypertensive patients: A systematic review and meta-analysis of randomized controlled trials” [PRO 175 (2024) 106914]. Prostaglandins & Other Lipid Mediators. https://www.sciencedirect.com/science/article/pii/S1098882326000456?dgcid=rss_sd_all
“Retraction notice to “Effects of aged garlic extract on blood pressure in hypertensive patients: A systematic review and meta-analysis of randomized controlled trials” [PRO 175 (2024) 106914].” Prostaglandins & Other Lipid Mediators.
@article{article62984,
title = {Retraction notice to “Effects of aged garlic extract on blood pressure in hypertensive patients: A systematic review and meta-analysis of randomized controlled trials” [PRO 175 (2024) 106914]},
journal = {Prostaglandins \& Other Lipid Mediators},
url = {https://www.sciencedirect.com/science/article/pii/S1098882326000456?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...